Quinazolinone based hydroxamates as anti-inflammatory agents

Bui Thi Buu Hue*, Hong Vinh Quang, Nguyen Cuong Quoc, and Tran Quang De
Department of Chemistry, College of Natural Sciences, Can Tho University, Viet Nam
*Correspondence: Bui Thi Buu Hue (email: btbhue@ctu.edu.vn)

Article info.
Received 20 Apr 2022
Revised 27 Apr 2022
Accepted 27 Apr 2022

ABSTRACT
Five thioether-linked hydroxamate/quinazolinone hybrid structures were synthesized and tested for their anti-inflammatory activities. The obtained results indicated that compounds 7a-c and 7e showed the inhibition on LPS-stimulated NO production with the IC50 values ranging from 58.03 to 66.19 μM. Molecular docking results showed that all synthesized compounds displayed affinity towards the 5-LOX, MK2, P2Y12, 15-PGDH, and DNA polymerase receptors based on the observed low binding energies and interactions with the key amino acids in the binding sites of the enzymes. Noticeably, compound 7e exhibited as a potential compound targeting six receptors including 5-LOX, MK2, mPGES-1, P2Y12, 15-PGDH, and DNA polymerase receptors.

Keywords
Anti-inflammatory, hydroxamates, molecular hybrid, in silico screening, quinazolinone

1. INTRODUCTION
Inflammation is a normal defense mechanism by the body's immune system in response to toxins, infectious pathogens, and local injury (Dkhil et al., 2018). However, persistent and untreated inflammation may lead to the development of certain diseases. Therefore, anti-inflammatory agents may be helpful in the management of inflammatory disorders (Moilanen, 2014). It has been found that the anti-inflammatory activity of many agents may originate mainly from their ability to inhibit some of the key enzymes involved in inflammation and/or cell signaling pathways such as cyclooxygenases (COXs) (Vane et al., 1998; Smith et al., 2000), lipoxygenases (LOXs) (Kühn & O'Donnell, 2006), protein kinase MK2 (Kotlyarov et al., 1999; Gaestel, 2006) 15-hydroxyprostaglandin dehydrogenase (15-PGDH) (Tai et al., 2011), prostaglandin E synthase-1 (Samuelsson et al., 2007), P2Y receptors (Kügelgen & Wetter, 2000), and DNA polymerase (Ishida et al., 2011). Thus, inhibition of these enzymes may be a valuable treatment for inflammatory conditions.

Recently, the combination of two or more pharmacophores of bioactive scaffolds to form hybrid analogues with improved potency has been extensively applied for the development of new drugs or drug candidates. The presence of two or more biologically active pharmacophores in one unit is expected to enhance the biological activity as well as increase its ability to interact with more than one biological target (Kerru et al., 2017).

Nitrogen-based heterocycles, especially 4(3H)-quinazolinone (also named as quinazolinone) and its derivatives have attracted great attention in the field of medicinal chemistry due to their diverse biological activities including anti-cancer (Chandrika et al., 2008; Wdowiak et al., 2021), antimicrobial (Kuyper et al., 1996), anti-convulsant (Archna et al., 2002; Georgey et al., 2008), antimalarial (Verhaeghe et al., 2008), anti-tumor (Abdel Gawad et al., 2010), and anti-inflammatory (Alagarsamy et al., 2007). On the other hand, the hydroxamate function, formally known as N-hydroxy-N-alkylamide, is found in various naturally occurring compounds and plays a key role in the...
iron acquisition mechanisms of microorganisms. Over the last few years, compounds containing hydroxamate function have been studied for many therapeutic applications including metal detoxification, anticancer, antioxidant, antibacterial and antifungal, antitumor, especially anti-inflammatory activities (Bertrand et al., 2013; Chen et al., 2015). Hybrid analogues containing 4(3H)-quinazolinones and hydroxamates have recently been reported as potent HDACs inhibitors for the treatment of cancer (Yang et al., 2016; Osipov et al., 2020; Bui et al., 2022) or Alzheimer’s disease (Yu et al., 2013). However, to the best of our knowledge, up to now, there has no report in the literature on the anti-inflammatory activity of 4(3H)-quinazolinone based hydroxamates. In the view of the facts mentioned above and also in an attempt to develop new potential anti-inflammatory agents, herein we report our initial results on the anti-inflammatory activity of five 4(3H)-quinazolinone based hydroxamate derivatives. Molecular docking studies were carried out to understand their activity.

2. MATERIALS AND METHODS

2.1. Materials

Reactions were monitored by thin-layer chromatography on 0.2-mm pre-coated silica gel 60 F254 plates (Merck). 1H-NMR and 13C-NMR spectra were measured with Bruker Avance 400 MHz, Bruker Avance 500 MHz, and Bruker Avance 600 MHz spectrometers. Mass spectrometry data were recorded on an 1100 series LC-MS-TrapLS Agilent spectrometer, and HR-ESI-MS observation was performed on a Bruker MicroTOF-Q mass spectrometer. FT-IR was conducted using the KBr pellet method with a Thermo Nicolet 6700. Chemical shifts are given in parts per million relative to tetramethylsilane (Me₄Si, δ = 0); J values are given in Hz. General procedures for the synthesis of the tested compounds can be found in the literature (Bui et al., 2022).

2.2. Nitric oxide assay

Briefly, RAW264.7 cells were grown in Minimum Essential Medium (α-MEM) supplemented with 1% penicillin-streptomycin solution and 10% Fetal Bovine Serum (FBS). When the cells reached about 70% confluency, they were harvested and diluted into fresh medium. Cell concentration was adjusted to 4 × 10^6 cells/mL. A total of 100 µL of cell suspension was seeded into a 96-well culture plate (4 × 104 cells/well) and incubated for 24 h at 37°C, in a humidified atmosphere containing 5% CO₂. Subsequently, 50 µL aliquots of 400 ng/mL of LPS and five different concentrations (50, 25, 12.5, 6.25, and 3.13 µM) of the isolated compounds and the positive control, L-NMMA were added to each well and incubated for 24 h. The supernatant (100 µL) from each well was transferred to another 96-well culture plate and combined with 100 µL of the Griess reagent (0.5% sulfanilamide and 0.05% N-1-naphthylethylene diamine dihydrochloride in 2.5% H₃PO₄), and then the reactions proceeded for 15 min at room temperature. The absorbance was recorded at 540 nm, using an SH-1200 microplate reader (Corona Electric). L-NMMA was used as a positive control. The percentages of NO inhibition were calculated by the following formula: % NO inhibition = 100 × [(Abs(control) – Abs(sample))/Abs(control)]; where Abs(control) and Abs(sample) are the absorbances of the control group treated with LPS alone and the absorbance of the samples.

2.3. Molecular docking studies

The ligands were optimized within the DFT at the B3LYP/6-31g(d,p) level by Gaussian programs (Frisch et al., 2009). The three-dimensional (3D) crystal structures of the cyclooxygenases-1 (ID PDB: 4O1Z), cyclooxygenases-2 (ID PDB: 4M11) 5-lipoxygenases (ID PDB: 3V99), protein kinase MK2 (ID PDB: 2JBP), 15-hydroxyprostaglandin dehydrogenase (ID PDB: 2GDZ), prostaglandin E synthase-1 (ID PDB: 5T37), P2Y receptors (ID PDB: 4NTJ), and DNA polymerase (ID PDB: 4MJQ) were obtained in the PDB format from RCSB. All water molecules (outside of the active site), small molecules, and co-crystallized ligand were deleted by Discovery Studio Visualizer program for docking protocol. The molecular docking study utilizes Flexx (Kramer et al., 1999) with assuming a rigid structure of protein and considering the conformational space of the ligands to analyze the inductive effect of the hybrid compounds. The binding sites include key amino acids within radius 7.00. The outputs of the docking studies were analyzed using Discovery Studio and the computer with core i7, 3.2 GHz processor.

3. RESULTS AND DISCUSSION

3.1. Chemistry

The four-step synthetic pathway towards the desired hybrid quinazolinone/hydroxamate derivatives bearing thioether linkage (7a-e) is presented in Figure 1. As described previously in the literature
starting from the commercially available isatoic anhydride (1), ring opening was taken place by appropriate amines (2a-e) under mild basic conditions to provide the corresponding 2-aminobenzamides (3a-e). Condensation reaction between (3a-e) and carbon disulfide was then conducted using a strong base as KOH to afford the quinazolinone core structures (4a-e) with the mercapto moiety being incorporated at the C-2 position of the heterocycle. The mercapto function was then further elaborated by introducing an ester substituent through a SN₂ nucleophilic substitution reaction with ethyl 2-chloroacetate (5) under mild basic conditions (K₂CO₃ in acetone) to provide thioether linkage containing quinazoliones (6a-e). The total yields over three steps were quite high (48-82%). Finally, aminolysis of the ester moiety took place by hydroxylamine hydrochloride to accomplish the desired hybrid structures quinazolinone/hydroxamic acid (7a-e). The total yields of the whole process (four steps) were moderate to good (14-69%). The structures of all synthesized compounds (7a-e) were firmly characterized based on reliable spectroscopic data including IR, HR-MS and NMR.

Figure 1. Developed synthetic pathway towards hybrid quinazolinone/hydroxamate derivatives bearing thioether linkage

3.2. Anti-inflammatory studies

Nitrogen oxide (NO), an important host defense effector in the immune system, is an important biological mediator in the living organism. However, the overproduction of NO which is catalyzed by iNOS, a soluble enzyme, is cytotoxic. On the other hand, NO is free oxygen radical and can act as a cytotoxic agent in pathological processes, particularly in inflammatory disorders (Moncada & Higgs, 1991; Alderton et al., 2001; Bogdan, 2001; Dawn & Bolli, 2002). Inhibition of NO production, therefore, may be beneficial for the treatment of inflammatory disease (Kröncke et al., 1998; Bogdan, 2001; Aktan et al., 2003).

The anti-inflammatory activities and cytotoxic effects of compounds 7a-e were evaluated by monitoring the NO inhibition activity and cell viability of LPS-induced RAW264.7 cells, respectively. The results are presented in Table 1 and Table 2.

The obtained data in Table 1 indicated that compounds 7a-c and 7e displayed the inhibition on LPS-stimulated NO production with the IC₅₀ values ranging from 58.03 to 66.19 μM, with the best result being observed for compound 7a (IC₅₀ = 58.03 μM) that was closely comparable with the control. Furthermore, compound 7a did not show any significant effect on cell proliferation at all tested concentrations. The obtained results could serve as the starting points for further structural design and modification to obtain lead compounds with potential anti-inflammatory activities.
Table 1. NO inhibition activity

| Samples   | Concentration (µM) | IC₅₀ (µM) |
|-----------|-------------------|----------|
|           | 6.25              | 12.5     | 25       | 50       | 100      |
| 7a        | 15.17 ± 3.29      | 21.26 ± 3.35 | 28.97 ± 1.72 | 47.82 ± 0.20 | 75.29 ± 2.11 | 58.03 ± 2.35 |
| 7b        | 13.45 ± 0.00      | 18.05 ± 1.21 | 28.74 ± 1.31 | 44.72 ± 1.39 | 71.04 ± 0.00 | 63.00 ± 1.02 |
| 7c        | 13.79 ± 0.60      | 20.46 ± 0.87 | 27.24 ± 1.24 | 42.30 ± 0.87 | 72.18 ± 0.80 | 63.08 ± 0.27 |
| 7d        | 14.37 ± 0.84      | 19.08 ± 0.91 | 28.02 ± 1.37 | 43.24 ± 0.42 | 62.80 ± 0.55 | 70.59 ± 1.06 |
| 7e        | 9.78 ± 3.32       | 17.63 ± 2.81 | 24.52 ± 2.72 | 37.20 ± 2.21 | 72.46 ± 1.88 | 66.19 ± 3.35 |
| L-NMMA    | 28.74 ± 1.51      | 40.70 ± 0.91 | 52.78 ± 1.11 | 61.96 ± 0.63 | 68.80 ± 0.00 | 37.11 ± 1.88 |

Table 2. Percentage of cell viability

| Samples   | Concentration (µM) | Percentage of cell viability (Mean ± SD) |
|-----------|-------------------|----------------------------------------|
|           | 6.25              | 12.5        | 25       | 50       | 100      |
| 7a        | 114.82 ± 0.31     | 123.40 ± 3.92 | 120.79 ± 2.87 | 120.65 ± 3.91 | 105.48 ± 7.98 |
| 7b        | 95.45 ± 3.68      | 93.63 ± 2.36 | 89.86 ± 4.68 | 80.80 ± 1.41 | 77.20 ± 2.41 |
| 7c        | 111.22 ± 1.76     | 110.75 ± 2.52 | 110.93 ± 2.66 | 109.99 ± 2.39 | 109.78 ± 2.02 |
| 7d        | 102.03 ± 3.96     | 103.58 ± 0.58 | 97.75 ± 1.56 | 90.33 ± 0.78 | 52.10 ± 1.74 |
| 7e        | 117.08 ± 2.74     | 120.30 ± 4.31 | 119.67 ± 2.13 | 118.22 ± 2.11 | 98.90 ± 8.34 |
| L-NMMA    | 109.22 ± 1.14     | 112.59 ± 2.07 | 115.03 ± 1.80 | 116.31 ± 1.26 | 110.59 ± 0.82 |

3.3. Docking results

Molecular docking is a fast and efficient computational method to predict the bioactive compounds to a specific protein or reversely predict the target proteins for one bioactive compound (Lee et al., 2016). In the aim to foresee the possible interactions of the synthesized compounds with the 5-LOX, COX-1, COX-2, MK2, mPGES-1, P2Y₁₂, 15-PGDH, and DNA polymerase, the molecular modeling simulations of 7a-e into the binding pockets of the enzymes were performed. The study was based on the hypothesis that the 2-mercaptopquinazolinone core structure of 7a-e possesses the ability to interfere with the active sites of the above target receptors and induces the inhibition of inflammation (Rajput & Singhal, 2013; Chaitanya et al., 2014).

The docking protocol was carried out by firstly redocking with the co-crystallized ligands into the receptors (Table 3 and Figure 2). The results showed that the root-mean-square-deviation (RMSD) values are all less than 2 Å, indicating the reliability of the docking model.

Table 3. Re-docking of bioactive co-crystallizers in the proposed sites of the receptors

| Target      | ID     | Co-crystallized inhibitor | RMS D (Å)g |
|-------------|--------|---------------------------|------------|
| 5-LOX       | 3V99   | Arachidonic acid¹       | -          |
| COX-1       | 4O1Z   | M XM b                    | 1.1807     |
| COX-2       | 4M11   | M XM b                    | 1.1477     |
| MK2         | 2JBP   | P4Q c                     | 0.9887     |
| mPGES-1     | 5T37   | 758 d                     | 1.9987     |
| P2Y₁₂       | 4NTJ   | AZJ e                     | 0.8092     |
| 15-PGDH     | 2GDZ   | -                         | -          |
| DNA polymerase | 4MJQ   | 27R f                     | 1.5197     |

Reference ligands and ID of receptors were named according to the RCSB protein data bank. ¹Substitution for diclofenac as previously described by Srivastava et al., 2016. ²Meloxicam. ³2-(2-quinoxolin-3-yl)pyridine-4-yl)-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one. ⁴2-chloro-5-[(2,2-dimethylpropanoyl)amino]methyl]-N-(1H-imidazol-2-yl)benzamide. ⁵ethyl 6-{4-[[benzylsulfonfyl]carbamoyl]piperidin-1-yl]-5-cyano-2-methylpyridine-3-carboxylate. ⁶Bromfenac; (-) Without a co-crystallization inhibitor or no RMSD value was calculated. ⁷RMSD values were calculated using LeadIT software.
The virtual screening was then conducted. The results showed that all the tested compounds exhibited the binding ability towards 5-LOX, COX-2, MK2, P2Y₁₂, 15-PGDH, and DNA polymerase receptors, with the binding energies lower than -10 kJ/mol, but with poor selectivity on the COX-1 receptor (Table 4). Specifically, compounds 7a, 7b, 7d, and 7e demonstrated the binding energies of -19.7423, -20.2687, -20.3706, and -19.6698 kJ/mol, respectively, on the 5-LOX receptor, which were lower than that of the control diclofenac. Noticeably, compounds 7e showed the highest potency on 5-LOX, mPGES-1, P2Y₁₂, 15-PGDH, and DNA polymerase receptors, with the predicted binding energy being lower than that of the controls. Most of the tested compounds formed interactions with key amino acid residues such as His372, His367, His550, Val671, and Phe177 at the binding site of 5-LOX. Three histidines (372, 367, and 550) formed polar hydrogen interactions with -C=O group of hydroxamate in a similar way as the nitro group of diclofenac (Figure 2). In particular, the nitro group of 7e showed polar interactions with Phe177, while the remaining compounds showed only hydrophobic interactions. This may be the cause for the observed lower binding energy of 7e at the binding site of 5-LOX compared to other compounds. Compounds 7b, 7d, and 7e were not successfully docked into the hydrophobic binding site of COX-1, which showed the positive values of the binding energy, suggesting unfavorable configuration for the targeted COX-1 receptor.

Table 4. Multitargeted molecular docking protocol of the synthesized compounds

| Ligand  | 5-LOX     | COX-1      | COX-2      | MK2       | mPGES-1   | P2Y₁₂     | 15-PGDH    | DNA polymerase |
|---------|-----------|------------|------------|-----------|-----------|-----------|------------|---------------|
| 7a      | -19.7423  | -9.1671    | -12.2080   | -20.1827  | -7.4103   | -23.3960  | -29.1612   | -11.5204      |
| 7b      | -20.2687  | ND         | -12.2469   | -19.1724  | -7.9871   | -21.0091  | -30.4524   | -11.5775      |
| 7c      | -17.8774  | -10.3131   | -12.8021   | -17.8822  | -4.4931   | -21.0668  | -30.3931   | -12.4451      |
| 7d      | -20.3706  | ND         | -11.1842   | -18.2803  | -2.9603   | -20.2148  | -27.7067   | -11.5551      |
| 7e      | -24.2066  | ND         | -12.7692   | -22.4516  | -13.1185  | -32.1360  | -31.9803   | -15.4975      |
| Diclofenac | -19.6698 |            |            |           |           |           |            |               |
| Meloxicam | -20.5138 | -21.4030  |            |           |           |           |            |               |
| P4O     |           |            |            |           | -24.1858  |           |            |               |
| 758     |           |            |            |           | -8.6743   |           |            |               |
| AZJ     |           |            |            |           | -30.4465  |           |            |               |
| 13<sup>a</sup> |       |            |            |           | -30.6314  |           |            | -13.0852      |
| Bromfenac |           |            |            |           |           |           |            |               |

<sup>a</sup>Piperidin-1-yl[1-(m-tolyl)-1H-benzof[d]imidazol-5-yl)methanone; ND: not docked; Reference ligand names were used according to the RCSB protein data bank.
Microsomal prostaglandin E synthase-1 (mPGES-1) is believed to be the main mediator of pain and inflammation. The selective mPGES-1 inhibitor may offer analgesic properties. Compound 7e was predicted to be a potential inhibitor for this receptor based on the observed lower binding energy compared to the control 758, a known mPGES-1 inhibitor (Partridge et al., 2017). Furthermore, the key amino acid Arg126 was found to simultaneously form polar interactions with the nitro and hydroxamate groups of 7e (Figure 3). Other interactions with Ser127 and Asn74 were also observed. These results are similar to the previously published docking model. The compound 758 showed direct interactions with the amino acids Asn74, Ser127, and Thr131, which were in accordance with the in vitro mPGES-1 inhibition results with an IC\textsubscript{50} value of 0.241 µM (Partridge et al., 2017).

![Figure 3](image-url)

**Figure 3.** Molecular docking results of compounds 7a (red), 7b (orange), 7c (yellow), 7d (blue), and 7e (green) at the active sites of the receptors (left) and interaction of the best compound 7e for each receptor (right). Blue surfaces indicate hydrophilicity and brown surfaces indicate hydrophobicity.

Protein kinase MK2 is a member of the p38 MAP kinase pathway, which is a key regulator of the inflammatory process. In 2007, Hillig et al. reported the first structure of MK2 in complex with P40, a high affinity MK2 inhibitor with an IC\textsubscript{50} value of 8.5 nM (Hillig et al., 2007). The docking results of 7a-e into MK2 showed that the hydroxamate groups formed hydrogen bonds with Asp207 at the binding site in a similar way as described for compound P40. Furthermore, hydrogen interactions were also observed between the ligand and amino acids such as Leu72, Lys188, and Asn191. These binding mode would open avenues for further optimization through structure-based design and development of promising MK2 inhibitors.
In the case of 15-PGDH receptor, all tested compounds indicated a favorable binding mode at the binding pocket site of the enzyme, with the binding energy around -30 kJ/mol, which was comparable to the control compound 13, a known 15-PGDH inhibitor with the IC50 value of 56 nM (Niesen et al., 2010). In contrast to the binding mode of compound 13, compounds 7a-e showed a more hydrophilic rather than hydrophobic binding mode. Several interactions have been observed between the hydroxamate groups and the hydrophilic amino acids Gln15, Asp36, and Asn91. The heterocyclic quinazolinone was oriented at the hydrophilic pocket site (Val94, Ala189, and Ile190). Noticeably, compound 7e, with the lowest binding energy (-31.9803 kJ/mol) among the tested compounds, had the phenyl substituent of the quinazolinone being oriented to the adjacent hydrophilic site (Trp37, Val65, Ala92, and Ile106) and the nitro group participated in hydrogen interaction with the hydrophilic amino acid Arg256.

Several generations of P2Y12-targeted antithrombotic drugs have been developed due to the critical functional role of this enzyme in platelet aggregation (Du & Liu, 2014). In 2014, the structure of the human P2Y12 receptor in a complex with an antithrombotic drug (ligand AJN, IC50 = 9 nM) was reported by Zhang (Zhang et al., 2014). The AZJ was found to accommodate the hydrophilic pocket Val102, Val190, Tyr105, Tyr109, Tyr194, Phe252, Arg256, Tyr259, and Leu276, with the predicted binding energy of -30.4465 kJ/mol. Our docking studies showed that compounds 7a-e formed polar hydrogen interactions with Arg256 in a similar way as AZJ. Especially, compound 7e displayed as the most potential compound with the binding energy of -32.1360 kJ/mol, which was lower than that of the control AZJ. Furthermore, 7e was oriented in a hydrophilic pocket and surrounded by key amino acids such as Tyr105, Tyr109, Asn191, and Phe252. Hydrogen interactions with amino acids His187, Asn159, Asn191, and Lys280 were also observed.

Some non-steroidal anti-inflammatory drugs (NSAIDs) have antibacterial properties. Targeting the DNA replication machinery, therefore, is a validated strategy for useful bacterial antibiotics (Yin et al., 2014). In this study, the tested compounds 7a-e were docked into the Escherichia coli DNA polymerase III β subunit using bromfenac as the reference. Bromfenac is a known nonsteroidal anti-inflammatory drug, which inhibited the E. coli DNA polymerase III β subunit with the Ks value of 193 μM (IC50 = 328 uM) (Yin et al., 2014). The docking results indicated that compounds 7a-e interacted with subsite I of the hydrophobic pocket in a manner similar to bromfenac. Compound 7e had the lowest free binding energy (-15.4975 kJ/mol) compared to other compounds and was lower than that of the reference bromfenac (-13.0852 kJ/mol). In addition, this compound formed three hydrogen bonds at the active site (NO2-Tyr154, NO2-Arg152, CONHOH-Asp243). Tyr154 and water molecules (HOH585) showed the same binding configuration with the nitro group as in the case of bromfenac, while the phenyl substituent and the quinazolinone ring oriented into the hydrophilic pocket (Arg240, Pro242, and Thr172).

In summary, docking-based virtual screening results indicated that compounds 7a-e showed affinity towards 5-LOX, MK2, P2Y12, 15-PGDH, and DNA polymerase receptors based on the observed low binding energies and interactions with the key amino acids in the binding sites of the enzymes. Noticeably, compound 7e exhibited as a potential compound targeting six receptors including 5-LOX, MK2, mPGES-1, P2Y12, 15-PGDH, and DNA polymerase receptors. These results in combination with the in vitro NO inhibition activity would be good references for further structure-based design and synthesis of active agents which can be used for the treatment of inflammatory disorders.

4. CONCLUSIONS

Five thioether-linked quinazolinone/hydroxamate hybrid derivatives 7a-e have been successfully synthesized in moderate to good total yields. The synthesized compounds exhibited moderate in vitro NO inhibition activities. Docking-based virtual screening results indicated that compounds 7a-e showed affinity towards 5-LOX, MK2, P2Y12, 15-PGDH, and DNA polymerase receptors. Noticeably, compound 7e exhibited as a potential compound targeting six receptors including 5-LOX, MK2, mPGES-1, P2Y12, 15-PGDH, and DNA polymerase receptors. These results indicate that quinazolinone conjugated hydroxamates are expected as potent candidates for discovery and development of anti-inflammatory drugs.

ACKNOWLEDGMENT

This research was funded by Vietnam Ministry of Education and Training (Grant number: B2020-TCT-12).
REFERENCES

Abdel, G. N. M., Georgey, H. H., Youssef, R. M., & El-Sayed, N. A. (2010). Synthesis and antitumor activity of some 2, 3-disubstituted quinazolin-4(3H)-ones and 4,6-disubstituted-1,2,3,4-tetrahydroquinazolin-2H-ones. European Journal of Medicinal Chemistry, 45(12), 6058–6067. https://doi.org/10.1016/j.ejmech.2010.10.008

Aktan, F., Henness, S., Roufogalis, B. D., & Ammit, A. J. (2003). Gypenosides derived from Gynostemma pentaphyllum suppress NO synthesis in murine macrophages by inhibiting iNOS enzymatic activity and attenuating NF-κB-mediated iNOS protein expression. Nitric Oxide, 8(4), 235–242. https://doi.org/10.1016/S1089-8603(03)00032-6

Alagarsamy, V., Meena, S., Ramaseshu, K. V., Solomon, V. R., Kumar, T. D. A., & Thirumurugan, K. (2007). Synthesis of Novel 3-Butyl-2-Substituted Amino-3H-Quinazolin-4-ones as Analgesic and Anti-Inflammatory Agents. Chemical Biology & Drug Design, 70(3), 254–260. https://doi.org/10.1111/j.1747-0285.2007.00548.x

Alderton, W. K., Cooper, c. e., & Knowles, R. G. (2001). Nitric oxide synthases: Structure, function and inhibition. Biochemical Journal, 357(3), 593–615. https://doi.org/10.1042/bj3570593

Archana, null, Srivastava, V. K., & Kumar, A. (2002). Synthesis of newer thiazolyl and thiazolidinonyl quinazolin-4 3H-ones as potential anticonvulsant agents. European Journal of Medicinal Chemistry, 37(11), 873–882. https://doi.org/10.1016/s0223-5234(02)01389-2

Bertrand, S., Helesbeux, J.-J., Larcher, G., & Duval, O. (2013). Hydroxamate, a Key Pharmacophore Exhibiting a Wide Range of Biological Activities. Mini Reviews in Medicinal Chemistry, 13(9), 1311–1326.

Bogdan, C. (2001). Nitric oxide and the immune response. Nature Immunology, 2(10), 907–916. https://doi.org/10.1038/ni1001-907

Bui, H. T. B., Nguyen, P. H., Pham, Q. M., Tran, H. P., Tran, D. Q., Jung, H., Hong, Q. V., Nguyen, Q. C., Nguyen, Q. P., Le, H. T., & Yang, S.-G. (2022). Target Design of Novel Histone Deacetylase 6 Selective Inhibitors with 2-Mercaptoquinazolinone as the Cap Moiety. Molecules, 27(7), 2204. https://doi.org/10.3390/molecules27072204

Chaitanya, P., Deepak Reddy, G., Varun, G., Srikanth, L. M., Prasad, V. V. S. R., & Ravindernath, A. (2014). Design and Synthesis of Quinazolinone Derivatives as Anti-inflammator Agents: Pharmacophore Modeling and 3D QSAR Studies. Medicinal Chemistry, 10(7), 711–723.

Chandrika, P. M., Yakaiah, T., Rao, A. R. R., Narasaih, B., Reddy, N. C., Sridhar, V., & Rao, J. V. (2008). Synthesis of novel 4,6-disubstituted quinazoline derivatives, their anti-inflammatory and anti-cancer activity (cytotoxic) against U937 leukemia cell lines. European Journal of Medicinal Chemistry, 43(4), 846–852. https://doi.org/10.1016/j.ejmech.2007.06.010

Chen, W.-C., Yen, C.-S., Huang, W.-J., Hsu, Y.-F., Ou, G., & Hsu, M.-J. (2015). WMJ-S-001, a novel aliphatic hydroxamate derivative, exhibit anti-inflammatory properties via MKP-1 in LPS-stimulated RAW264.7 macrophages. British Journal of Pharmacology, 172(7), 1894–1908. https://doi.org/10.1111/bph.13040

Dawn, B., & Bolli, R. (2002). Role of Nitric Oxide in Myocardial Preconditioning. Annals of the New York Academy of Sciences, 962(1), 18–41. https://doi.org/10.1111/j.1749-6632.2002.tb04053.x

Dkhi, M. A., Kassab, R. B., Al-Quraishy, S., Abdel-Daim, M. M., Zrieq, R., & Abdel Moneim, A. E. (2018). Ziziphus spina-christi (L.) leaf extract alleviates myocardial and renal dysfunction associated with sepsis in mice. Biomedicine & Pharmacotherapy, 102, 64–75. https://doi.org/10.1016/j.biopha.2018.03.032

Du, B., & Liu, M. (2014). Structure of the human P2Y12 receptor in complex with an antithrombotic drug. Science China Life Sciences, 57(6), 645–646. https://doi.org/10.1007/s11427-014-4659-5

Frisch, M., Trucks, G., Schlegel, H. B., Scuseria, G. E., Robb, M. A., Cheeseman, J. R., Scalmani, G., Barone, V., Mennucci, B., & Peterson, Ga. (2009). gaussian 09, Revision d. 01, Gaussian.

Gaestel, M. (2006). MAPKAP kinases—MKs—Two’s a crowd. Nature Reviews Molecular Cell Biology, 7(2), 120–130. https://doi.org/10.1038/nrm1834

Georgey, H., Abdel-Gawad, N., & Abbas, S. (2008). Synthesis and Anticonvulsant Activity of Some Quinazolin-4(3H)-one Derivatives. Molecules, 13(10), 2557–2569. https://doi.org/10.3390/molecules13102557

Hillig, R. C., Eberspaecher, U., Monteclaro, F., Huber, M., Nguyen, D., Mengel, A., Muller-Tiemann, B., & Egner, U. (2007). Structural Basis for a High Affinity Inhibitor Bound to Protein Kinase MK2. Journal of Molecular Biology, 369(3), 735–745. https://doi.org/10.1016/j.jmb.2007.03.004

Ishida, T., Mizushima, Y., Yagi, S., Irino, Y., Nishiumi, S., Miki, I., Kondo, Y., Mizuno, S., Yoshida, H., Azuma, T., & Yoshida, M. (2011). Inhibitory Effects of Glycyrrhetinic Acid on DNA Polymerase and Inflammatory Activities. Evidence-Based Complementary and Alternative Medicine, 2012, e650514. https://doi.org/10.1155/2012/650514

Kerru, N., Singh, P., Koobranally, N., Raj, R., & Kumar, V. (2017). Recent advances (2015–2016) in
anticancer hybrids. *European Journal of Medicinal Chemistry, 142*, 179–212. https://doi.org/10.1016/j.ejmech.2017.07.033

Kotlyarov, A., Neininger, A., Schubert, C., Eckert, R., Birchmeier, C., Volk, H.-D., & Gaestel, M. (1999). MAPKAP kinase 2 is essential for LPS-induced TNF-α biosynthesis. *Nature Cell Biology, 1*(2), 94–97. https://doi.org/10.1038/10061

Kramer, B., Rarey, M., & Lengauer, T. (1999). *Kramer, B., Rarey, M., & Lengauer, T. (1999).*

Kotlyarov, A., Neininger, A., Schubert, C., Eckert, R., Birchmeier, C., Volk, H.-D., & Gaestel, M. (1999). MAPKAP kinase 2 is essential for LPS-induced TNF-α biosynthesis. *Nature Cell Biology, 1*(2), 94–97. https://doi.org/10.1038/10061

Kramer, B., Rarey, M., & Lengauer, T. (1999). Evaluation of the FLEXX incremental creation algorithm for protein–ligand docking. *Proteins: Structure, Function, and Bioinformatics, 37*(2), 228–241. https://doi.org/10.1002/1097-0134(19991101)37:2<228::AID-PROT8>3.0.CO;2-8

Kröncke, K.-D., Fehsel, K., & Kolb-Bachofen, V. (1998). Inducible nitric oxide synthase in human diseases. *Clinical and Experimental Immunology, 113*(2), 147–156. https://doi.org/10.1046/j.1365-2249.1998.00648.x

Kügelen, I. V., & Wetter, A. (2000). Molecular pharmacology of P2Y-receptors. *Naunyn-Schmiedeberg’s Archives of Pharmacology, 362*(4), 310–323. https://doi.org/10.1007/s002100000310

Kühn, H., & O’Donnell, V. B. (2006). Inflammation and immune regulation by 12/15- lipoxigenases. *Progress in Lipid Research, 45*(4), 334–356. https://doi.org/10.1016/j.plipres.2006.02.003

Kuyper, L. F., Baccanari, D. P., Jones, M. L., Hunter, R. N., Tansik, R. L., Joyner, S. S., Boytos, C. M., Rudolph, S. K., Knick, V., Wilson, H. R., Caddell, J. M., Friedman, H. S., Comley, J. C. W., & Stables, J. R. (1996). High-Affinity Inhibitors of Dihydrofolate Reductase: Antimicrobial and Anticancer Activities of 7,8-Dialkyl-1,3-diaminopyrrolo[3,2-d]quinazolines with Small Molecular Size. *Journal of Medicinal Chemistry, 39*(4), 892–903. https://doi.org/10.1021/jm9505122

Moilanen, E. (2014). Two Faces of Inflammation: An Immunopharmacological View. *Basic & Clinical Pharmacology & Toxicology, 114*(1), 2–6. https://doi.org/10.1111/bcpt.12180

Moncada, S., & Higgs, E. A. (1991). Endogenous nitric oxide: Physiology, pathology and clinical relevance. *European Journal of Clinical Investigation, 21*(4), 361–374. https://doi.org/10.1111/j.1365-2362.1991.tb01383.x

Niesen, F. H., Schultz, L., Jadhav, A., Bhatia, C., Guo, K., Maloney, D. J., Pilka, E. S., Wang, M., Oppermann, U., Heightman, T. D., & Simeonov, A. (2010). High-Affinity Inhibitors of Human NAD+ Dependent 15-Hydroxyprostaglandin Dehydrogenase: Mechanisms of Inhibition and Structure-Activity Relationships. *PLoS ONE, 5*(11), e13719. https://doi.org/10.1371/journal.pone.0013719

Nwet N. W., Besse H., Hla N., Yoshihiro H. and Hiroyuki M. (2020). Anti-inflammatory activities of isopimara-8(9),15-diene diterpenoids and mode of action of kaempulchraols B-D from Kaempferia pulchra rhizomes. *Journal of Natural Medicines, 74*, 487–494.

Osipov, V. N., Khachatryan, D. S., & Balaev, A. N. (2020). Biologically active quinazoline-based hydroxamic acids. *Medicinal Chemistry Research, 29*(5), 831–845. https://doi.org/10.1007/s00044-020-02530-7

Partridge, K. M., Antonysamy, S., Bhattachar, S. N., Chandrasekhar, S., Fisher, M. J., Fretiland, A., Gooding, K., Harvey, A., Hughes, N. E., Kuklish, S. L., Luz, J. G., Manninen, P. R., McGee, J. E., Mudra, D. R., Navarro, A., Norman, B. H., Quimby, S. J., Schiffer, M. A., Sloan, A. V., ..., Yu, X.-P. (2017). Discovery and characterization of [(cyclopentyl)ethyl]benzoic acid inhibitors of microsomal prostaglandin E synthase-1. *Bioorganic & Medicinal Chemistry Letters, 27*(6), 1478–1483. https://doi.org/10.1016/j.bmcl.2016.11.011

Rajput, C. S., & Singhal, S. (2013). Synthesis, Characterization, and Anti-Inflammatory Activity of Newer Quinazolone Analogs. *Journal of Pharmaceutics, 2013*, e907525. https://doi.org/10.1155/2013/907525

Samuelsson, B., Morgenstern, R., & Jakobsson, P.-J. (2007). Membrane Prostaglandin E Synthase-1: A Novel Therapeutic Target. *Pharmacological Reviews, 59*(3), 207–224. https://doi.org/10.1124/pr.59.3.1

Smith, W. L., DeWitt, D. L., & Garavito, R. M. (2000). Cyclooxygenases: Structural, Cellular, and Molecular Biology. *Annual Review of Biochemistry, 69*(1), 145–182. https://doi.org/10.1146/annurev.biochem.69.1.145

Srivastava, P., Vyas, V. K., Variya, B., Patel, P., Qureshi, G., & Ghave, M. (2016). Synthesis, anti-inflammatory, analgesic, 5-lipoxygenase (5-LOX) inhibition activities, and molecular docking study of 7-substituted coumarin derivatives. *Bioorganic chemistry, 67*, 130–138.

Tai, H.-H., Chi, X., & Tong, M. (2011). Regulation of 15-hydroxyprostaglandin dehydrogenase (15-PGDH) by non-steroidal anti-inflammatory drugs (NSAIDs). *Prostaglandins & Other Lipid Mediators, 96*(1), 37–40. https://doi.org/10.1016/j.prostaglandins.2011.06.005

Vane, J. R., Bakhle, Y. S., & Botting, R. M. (1998). Cyclooxygenases 1 and 2. *Annual Review of Pharmacology and Toxicology, 38*(1), 97–120. https://doi.org/10.1146/annurev.pharmtox.38.1.97

Verhaeghe, P., Azas, N., Gasquet, M., Hutter, S., Ducros, C., Laget, M., Rault, S., Rathelot, P., & Vanelle, P. (2008). Synthesis and antiplasmodial activity of new 4-aryl-2-trichloromethylquinazolines. *Bioorganic & Medicinal Chemistry Letters, 18*(1), 396–401. https://doi.org/10.1016/j.bmcl.2007.10.027

Wdowiak, P., Matysiak, J., Kusza, P., Czarnek, K., Niezbzitowska, E., & Baj, T. (2021). Quinazoline
Derivatives as Potential Therapeutic Agents in Urinary Bladder Cancer Therapy. *Frontiers in Chemistry*, 9, 765552. https://doi.org/10.3389/fchem.2021.765552

Yang, Z., Wang, T., Wang, F., Niu, T., Liu, Z., Chen, X., Long, C., Tang, M., Cao, D., Wang, X., Xiang, W., Yi, Y., Ma, L., You, J., & Chen, L. (2016). Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer. *Journal of Medicinal Chemistry*, 59(4), 1455–1470. https://doi.org/10.1021/acs.jmedchem.5b01342

Yin, Z., Wang, Y., Whittell, L. R., Jergic, S., Liu, M., Harry, E., Dixon, N. E., Kelso, M. J., Beck, J. L., & Oakley, A. J. (2014). DNA Replication Is the Target for the Antibacterial Effects of Nonsteroidal Anti-Inflammatory Drugs. *Chemistry & Biology*, 21(4), 481–487. https://doi.org/10.1016/j.chembiol.2014.02.009

Yu, C.-W., Chang, P.-T., Hsin, L.-W., & Chern, J.-W. (2013). Quinazolin-4-one Derivatives as Selective Histone Deacetylase-6 Inhibitors for the Treatment of Alzheimer’s Disease. *Journal of Medicinal Chemistry*, 56(17), 6775–6791. https://doi.org/10.1021/jm400564j

Zhang, K., Zhang, J., Gao, Z.-G., Zhang, D., Zhu, L., Han, G. W., Moss, S. M., Paoletta, S., Kiselev, E., Lu, W., Fenalti, G., Zhang, W., Müller, C. E., Yang, H., Jiang, H., Cherezov, V., Katritch, V., Jacobson, K. A., Stevens, R. C., … Zhao, Q. (2014). Structure of the human P2Y12 receptor in complex with an antithrombotic drug. *Nature*, 509(7498), 115–118. https://doi.org/10.1038/nature13083